Top Markets
Coin of the day
Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.

ANTH
Rank in Stocks #42276
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on... Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$2.62K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Anthera Pharmaceuticals, Inc. (ANTH)

Category

P/B ratio for Anthera Pharmaceuticals, Inc. (ANTH)
P/B ratio as of 2026 TTM: 0
According to Anthera Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Anthera Pharmaceuticals, Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR